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Abstract
Objective—The goal of this study was to test the ability of an injectable self-assembling peptide
(KLD) hydrogel with or without chondrogenic factors (CF) and allogeneic bone marrow stromal
cells (BMSCs) to stimulate cartilage regeneration in a full-thickness, critically-sized, rabbit
cartilage defect model in vivo. We used CF treatments to test the hypotheses that CF would
stimulate chondrogenesis and matrix production by cells migrating into acellular KLD (KLD+CF)
or by BMSCs delivered in KLD (KLD+CF+BMSCs).
Design—Three groups were tested against contralateral untreated controls: KLD, KLD+CF, and
KLD+CF+BMSCs, n=6–7. TGF-β1, dexamethasone, and IGF-1 were used as chondrogenic
factors (CF) pre-mixed with KLD and BMSCs before injection. Evaluations included gross,
histological, immunohistochemical and radiographic analyses.
Results—KLD without CF or BMSCs showed the greatest repair after 12 weeks with
significantly higher Safranin-O, collagen II immunostaining, and cumulative histology scores than
untreated contralateral controls. KLD+CF resulted in significantly higher aggrecan
immunostaining than untreated contralateral controls. Including allogeneic BMSCs+CF markedly
reduced the quality of repair and increased osteophyte formation compared to KLD alone.
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Conclusions—These data show that KLD can fill full-thickness osteochondral defects in situ
and improve cartilage repair as shown by Safranin-O, collagen II immunostaining, and cumulative
histology. In this small animal model, the full-thickness critically-sized defect provided access to
the marrow, similar in concept to abrasion arthroplasty or spongialization in large animal models,
and suggests that combining KLD with these techniques may improve current practice.
Keywords
Bone marrow derived mesenchymal stem cells; cartilage; tissue engineering; rabbit model; self-
assembling peptide scaffold
INTRODUCTION
Repair of articular cartilage injuries remains a challenge, despite the development of surgical
treatments such as microfracture, abrasion arthroplasty, and spongialization, which are used
with the goal of recruiting marrow-derived cells by penetration of the subchondral bone.
While these techniques promote increased short-term healing, long-term repair still consists
of mechanically-inferior fibrocartilage1. Recent research has focused on tissue engineering
strategies using scaffolds to improve cartilage repair and regeneration. In particular,
hydrogels made from materials such as chitosan-glycerol phosphate2, polyethyleneglycol
(PEG)3, fibrin4, polyglycolic-co-lactic acid (PLGA)5, and collagen6 have been explored
with the goal of improving the accumulation of extracellular matrix produced by cells (e.g.,
bone marrow stromal cells (BMSCs)) migrating into the scaffold from marrow.
Stimulation of BMSC chondrogenesis in vitro and in vivo has received much attention. In
vitro studies have shown that transforming growth factor-β1 (TGF-β1), dexamethasone, and
insulin-like growth factor-1 (IGF-1) promote chondrogenesis of BMSCs7–11, and methods
for delivering these chondrogenic factors have been developed, often in conjunction with
scaffolds12–15. There have been a number of in vivo studies performed delivering IGF-14,16,
TGF-β11,17,18, or the combination of IGF-1 and TGF-β113,16,19 to cartilage defects in order
to stimulate chondrogenesis of endogenous BMSCs, but to our knowledge, no in vivo studies
have incorporated dexamethasone.
The hypothesis that delivery of exogenous BMSCs to the joint can enhance cartilage
regeneration has prompted the exploration of a wide variety of growth factor and scaffold
combinations to stimulate BMSC chondrogenesis1,20,21. In vivo studies have attempted to
deliver BMSCs alone22,23, BMSCs encapsulated in scaffolds24–26, and BMSCs
encapsulated in scaffolds with the inclusion of TGF-β127–30. Despite the in vitro promise
shown by 3D-cultured BMSCs, most long-term in vivo treatments with BMSCs have
resulted in sub-optimal cartilage repair tissue20,22,24,26. Improving BMSC chondrogenesis
in vivo is likely dependent on several factors that are not well understood, including cell
delivery, microenvironment, and a combination of pro-chondrogenic longitudinal signaling.
In addition, an ideal clinical approach would minimize or obviate the in vitro culture
duration and be performed with a single arthroscopic procedure.
Recent studies have shown that hydrogels made from the self-assembling peptide sequences
(RADA)4 and (KLDL)3 (hereafter referred to as KLD) can maintain the chondrocyte
phenotype31 and stimulate chondrogenesis of BMSCs in vitro32–34. These hydrogels have
the ability to rapidly assemble when exposed to physiological pH and ionic strength35 and
have pore sizes in the range of 100–500 nm36. These synthetic peptides have been used in
vivo without immunogenic reaction37. Furthermore, TGF-β1 has been shown to adsorb to
KLD when pre-mixed with the peptide solution prior to assembly, resulting in extended
delivery of TGF-β1 to BMSCs and stimulating chondrogenesis in vitro, promoting sGAG
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production and accumulation comparable to continuous medium supplementation of TGF-β1
over 21 days38. In addition, including dexamethasone with TGF-β1 in medium
supplementation during the in vitro culture of BMSCs in RADA results in less catabolic
cleavage of aggrecan compared to culture with TGF-β1 alone39. Finally, IGF-1 can be
tethered to peptide scaffolds via biotin-streptavidin bonds; this tethered IGF-1 has been
shown to remain biologically active and to promote cell survival in rat cardiomyocytes over
28 days37.
The goal of this study was to test the ability of an injectable KLD hydrogel with or without
BMSCs and chondrogenic factors (CF) to stimulate cartilage regeneration in vivo in a
critically-sized rabbit full-thickness cartilage defect model. This model provides access to
the marrow, analogous to abrasion arthroplasty or spongialization in large animal models.
We used CF treatments (IGF-1, TGF-β1, and dexamethasone) to test the hypotheses that CF
would stimulate chondrogenesis and matrix production (1) by cells migrating into acellular
KLD and (2) by P2 passaged allogeneic BMSCs delivered in KLD. IGF-1 was tethered to
the peptide with a biotin-streptavidin bond37 to stimulate long-term production of cartilage
ECM, while TGF-β1 and dexamethasone were pre-mixed with KLD prior to BMSC
encapsulation to stimulate chondrogenesis and initial matrix production. A 12-week
timepoint enabled evaluation of mid-term benefits of the treatment compared to contralateral
untreated defects.
METHODS
Materials
KLD peptide with the sequence AcN-(KLDL)3-CNH2 was synthesized by the MIT
Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide synthesizer
with FMOC protection. Human recombinant TGF-β1 (R&D Systems, Inc., Minneapolis,
MN), dexamethasone (Sigma-Aldrich, St. Louis, MO), sucrose (Sigma-Aldrich),
biotinylated-IGF-1 (bIGF-1) (immunological and biochemical testsystems GmbH,
Reutlingen Germany), streptavidin (Pierce Biotechnology, Inc, Rockford, IL), biotinylated-
KLD (biotin-(aminocaproic acid)3-(KLDL)3 or b-KLD) (MIT Biopolymers Laboratory),
FBS (Invitrogen, Carlsbad, CA), and FGF-2 (R&D Systems, Inc.) were purchased and used
as described.
Cell Isolation
Bone marrow was harvested and pooled from four rabbits used for an initial pilot study, and
BMSCs were isolated as previously described34. BMSCs were selected via differential
adhesion to plastic and expanded two passages in alphaMEM with 10% FBS and 2 ng/mL
FGF-2, 10 mM HEPES, and PSA (100 U/mL penicillin, 100 μg/mL streptomycin, and 250
ng/mL amphotericin), resulting in a total of approximately four population doublings. Each
passage was conducted by seeding at a concentration of 12×103 BMSCs/cm2 and incubating
for two days to allow BMSCs to grow to ~75% confluence.
In Vivo Study Design
All procedures were approved by the Animal Care and Use Committees at Colorado State
University and Massachusetts Institute of Technology. Twenty skeletally mature, retired,
female breeder New Zealand White rabbits (average age 11 months and body weight 4.7 kg)
were used for this study (Myrtle’s Rabbitry, Thompson Station, TN). One rabbit died during
the study due to neurologic problems post-surgery and was not included in the analysis. The
n values shown in Table 1 do not reflect this animal. Three different groups were tested
against contralateral, untreated, empty controls: (1) KLD, (2) KLD+chondrogenic factors
(CF), and (3) KLD+CF+BMSCs (Table 1). For all groups, KLD was resuspended in 10%
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sterile sucrose, and the final KLD concentration was kept constant at 3.2 mg/mL. For groups
2 and 3, KLD peptide (48 μg) was pre-mixed with a CF mixture consisting of 1.4 ng TGF-
β1, 0.6 ng dexamethasone, 4.1 ng biotinylated-IGF-1 (bIGF-1), 30.7 ng streptavidin, and
0.48 μg b-KLD. For group 3, 150×103 BMSCs were encapsulated in the KLD/CF mixture34.
Encapsulation of BMSCs in vitro in this manner resulted in 80–90% viability. In vitro
studies indicated that this amount of TGF-β1 would result in a concentration of TGF-β1
inside the scaffold sufficient to stimulate chondrogenesis38. At the same time, if all of the
TGF-β1 were to be released from the scaffold at once into the joint space in vivo, it would
amount to approximately 1 ng/mL concentration in the joint space (1.4 ng/1.4 mL joint
space volume40), compared to the native concentration of 52.3 pg/mL found in adult
rabbits40. Streptavidin and bIGF-1 were mixed at a 1:1 molar ratio in order to achieve, on
average, binding of one bIGF-1 to each streptavidin allowing streptavidin to still bind b-
KLD (in 100x molar excess of streptavidin and bIGF-1 to ensure homogeneous distribution
of IGF-1 throughout the gel). The ability of this tethering to occur using these molar ratios
has been shown in vitro and in vivo37. The amount of bIGF-1 tethered was chosen to provide
a local concentration of 300 ng/mL inside the scaffold, which is above the threshold shown
to be sufficient for chondrocyte stimulation of proteoglycan synthesis in vivo41.
Defect Creation and Gel Injection
All surgical procedures were performed under inhalation general anesthesia. A medial-
parapatellar arthrotomy approach to the femoropatellar joint was performed, and the patella
was luxated laterally. A 3mm-diam × 2mm-deep full-thickness, critically-sized defect was
created in the central region of the femoral trochlear groove (Fig 1). Direct pressure was
applied with a surgical sponge to ensure all bleeding was stopped prior to application of the
peptide, which was delivered as a liquid. Defects were filled with designated treatments (15
μL volume) or left untreated, as dictated by group assignment. The liquid peptide suspension
could easily be seen filling the defect, and defects were filled until visually full. At this time,
Lactated Ringer’s Solution was added to the joint periphery to gently fill the joint and cause
polymerization of the peptide, which was visually inspected to ensure retention of the
implant. Dorsal-caudal and lateral-medial 90° radiographs of each stifle joint were obtained
immediately after surgery. At 12 weeks, rabbits were euthanized with pentobarbital after
sedation. Post-surgical radiographic views were repeated following euthanasia.
Gross Pathologic Observations of Joints
The limbs and joints were examined and graded by a blinded observer (DDF) unaware of
treatment group (Table 2). For the muscle wastage measurement, the limbs were shaved and
a flexible tape measure was used in a similar anatomic location of the stifle to make this
assessment. This scoring system was chosen in order to compare to other studies performed
by Frisbie et al.6
Synovial Membrane Histology
Synovial membrane was harvested and placed in neutral-buffered 10% formalin, embedded
in paraffin, 5-μm sections created and stained with hematoxylin and eosin (H&E). Sections
were evaluated blindly (DDF) for cellular infiltration, vascularity, intimal hyperplasia,
subintimal edema and subintimal fibrosis on a scale of 0–4 (0=none, 1=slight, 2=mild,
3=moderate, 4=severe)42.
Articular Cartilage Histology and Immunohistochemistry
At the time of necropsy, the circular defect area was cut in half with an Exakt bandsaw. The
medial half of the repair tissue with surrounding native tissue was fixed in neutral-buffered
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10% formalin for histology, and the lateral half was embedded in OCT and flash frozen for
immunohistochemistry.
For histology, the fixed tissue was decalcified, embedded in paraffin, sectioned at 5 μm, and
stained with either H&E or Safranin-O, fast green (SOFG) (ThermoScientific/Shandon
VeriStain Gemini ES stainer) for proteoglycan visualization. Sections stained with H&E
were evaluated blindly (DDF) using a modified O’Driscoll scoring system6,43 (Table 3) with
a maximum cumulative histology score of 28 and a higher score indicating a repair more
like native cartilage. Sections stained with SOFG were evaluated blindly (DDF) for intensity
of staining on a scale of 0–3 (Table 3) and were included in the cumulative histology score.
For immunohistochemical analyses, frozen tissue was sectioned at 8 μm. Each section was
incubated in 0.25 U/mL chondroitinase ABC (Sigma-Aldrich) for 15 min before incubation
in primary antibody solution (Collagen I (1:10) #M-38-s and II (undiluted) # II-II6B3-s,
Hybridoma Bank; Aggrecan (1:100, Alexis Biochemicals) #ALX-803-313; or rabbit IgG as
control). Endogenous peroxidase was blocked using 0.3% H2O2 in methanol. Sections were
incubated in goat anti-mouse HRP secondary antibody solution (1:500, Jackson
Immunoresearch, Westgrove, PA)), stained with Vector Nova RED (Vector Laboratories,
Burlingame, CA) and counterstained with Fast Green. Controls gave no signal. Non-
calcified tissues were evaluated blindly (DDF) for the percentage of repair tissue stained
positive (0=no stain, 1=1–25%, 2=26–50%, 3=51–75%, 4=76–100%).
Radiographic Analysis
Radiographs and photographs were taken of bone segments from femoral sections.
Radiographs were graded for presence of lysis, bony proliferation, osteophyte presence, and
patellar luxation, and a total radiographic score was calculated by summing these scores
(maximum score of 16). All grading was done on a 0–4 scale (0=none, 1=slight, 2=mild,
3=moderate, 4=severe)22,42. Additionally, radiographs post-euthanasia were scored for
healing of the defect (0=no healing, 1=slight healing, 2=mild bone filling, 3=lesion is visible
but difficult to measure, 4=lesion not visible to measure), sclerosis around the defect, and
other sclerosis (0–4, none-severe). Sclerosis is defined as the increase in density of bone
seen radiographically and was subjectively scored by MFB in a blinded fashion.
Statistical Analyses
Scores were evaluated for inter- and intra-group differences using an ANOVA framework
with PROC GLIMMIX (fits generalized linear mixed models) of SAS (Cary, NC)44 with
rabbit as a random variable. For all joint pathologic, histological, immunohistochemical, and
radiographic analyses, intra-group differences were analyzed with treatment set as the main
effect (one-way); differences among groups were analyzed using treatment and group as
main effects (two-way). Untreated controls were therefore analyzed separately depending on
what treatment the contralateral joint received in order to account for possible systemic
effects45. When main or interaction effects had p-values that were considered significant (p-
value < 0.05) or a trend (0.05 < p-value <0.10), individual comparisons were made using the
least square means procedure22. P-values presented in the text include which main effect or
interaction term they are referring to if quoted for comparisons among groups. All data are
presented as mean ± standard error of the mean (SEM). Non-parametric analyses were also
performed when appropriate. The authors were able to reach similar conclusions based on
either analysis. Because the authors feel many of the biologic outcome parameters represent
more of a continuum rather than defined categories, the parametric analysis of the data is
presented.
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RESULTS
Radiographic Analyses
Radiographic analyses pre-treatment did not show any sclerosis in any of the rabbits.
Treated defects post-treatment showed some slight osteophyte formation (0.3 (0.0, 0.6),
treated; 0.1 (−0.2, 0.4), untreated; treatment p=0.087). There was no difference among
groups (group p=0.490).
Gross Observation of Joints
Upon necropsy, joints and incision areas in all experimental groups appeared normal by
gross examination (Fig 1), and no inflammation or infection was noted, indicating no
adverse immune reaction to the treatments. Repair cartilage appeared to be moderately to
normally attached to surrounding cartilage in all defects with no differences between
treatments (treatment p=0.299) or groups (group p=0.541) (Table 4:XIII). Similarly, repair
tissue ranged from normal to slightly-soft compared to surrounding tissue when assessed for
attachment to the subchondral bone, with no differences between treatments (treatment
p=0.192) or groups (group p=0.970) (Table 4:XIV). Rabbits receiving KLD+CF+BMSCs
(group 3) demonstrated mild osteophyte formation, with an increased score compared to
KLD-alone (group 1) (group p=0.029) (Table 4:VIII). Treated defects in group 3 also had
better attachment to subchondral bone compared to untreated defects in group 3 (p=0.030)
(Table 4:XIV). Overall, treated defects had an increased defect volume filled (91.4 (82.3,
100.4), treated vs. 78.2 (69.1, 87.3), untreated, treatment p= 0.032) and the level of treated
defects was higher than contralateral untreated defects (2.6 (2.3, 3.0), treated; 2.2 (1.8, 2.6),
untreated; treatment p=0.050). Untreated defects also had more muscle wastage at the site of
incision (assessed by circumferential measurement at the proximal aspect of the patella)
(12.9 cm (12.5, 13.2), treated vs. 12.7 cm (12.3, 13.0), untreated; treatment p=0.001), with
group 1 and 3 treated defects different from their respective contralateral controls (Table
4:III; interaction p=0.032). Treated defects were scored higher in grade of repair compared
to contralateral untreated defects, equivalent to a score of good (3.0 (2.6, 3.5), treated vs. 2.5
(2.0, 2.9), untreated, on a scale of 0–4; treatment p=0.061).
Histologic Examinations
Synovial Membrane H&E: Evaluation of the synovial membrane by H&E staining showed
some mild intimal hyperplasia and some mild to moderate vascularity and subintimal
fibrosis, but there were no differences among any groups or treatments.
Articular Cartilage H&E: Assessment of the articular cartilage H&E staining showed that
KLD (group 1) had a higher cumulative histology score compared to contralateral untreated
controls when looking at that group alone (Table 5:XII, p=0.034). Overall, when comparing
among groups, KLD and KLD+CF (groups 1 and 2) had higher cumulative scores than KLD
+CF+BMSCs (group 3) (Table 5:XII, group p=0.030). Defects treated with KLD received
the highest score for nature of predominant tissue in the defect (see Tables 3, 5:I), which
was similar to fibrocartilage. The other groups and treatments ranged between 0 and 1,
indicating presence of some fibrocartilage and some non-chondrocytic cells; however, none
of the groups or treatments were significantly different (Table 5:I, group p=0.749, treatment
p=0.264). Group 3 had significantly lower surface regularity with scores indicative of some
fissuring of the surface (Tables 3,5:II, group p=0.005) and more degenerative change in
cartilage surrounding the defect, showing mild to moderate hypocellularity compared to
KLD and KLD+CF (Tables 3,5:VIII, group p=0.015). Group 2 had more reconstitution of
subchondral bone than group 3 (group p=0.030), but all groups were still below normal
subchondral bone levels (Tables 3,5: IX); treated defects trended higher than untreated
defects (1.9 (1.5, 2.2) treated; 1.5 (1.1, 1.8) untreated; treatment p=0.074). Group 2 also
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showed the highest score for bonding to adjacent cartilage (Table 5:V), but no groups or
treatments were significantly different (treatment p=0.161, group p=0.226). Treated defects
had increased cellularity (Table 3:VI) compared to contralateral untreated defects (treatment
p=0.031) showing normal to slight hypocellularity in the treated defects repair tissue (1.8
(1.5, 2.0) treated; 1.6 (1.3, 1.8) untreated); group 3 trended higher than the other groups (2.0
(1.7, 2.3) group 3; 1.5 (1.1, 1.9) groups 1 and 2; group p=0.081).
Articular Cartilage SOFG—Defects treated with KLD-alone (group 1) had increased
Safranin-O staining (scores of slight to moderate staining) than the contralateral untreated
defects or treated defects in groups 2 and 3, which had only none to slight staining (Table
5:XI, interaction p=0.011). There was no overall effect of treatment or group on this
measure (treatment p=0.286, group p=0.604). As shown in Fig 2, treatment with KLD-alone
resulted in greater staining throughout the repair tissue.
Immunohistochemistry Evaluations
Looking at only group 1, defects treated with KLD showed increased collagen II
immunostaining compared to contralateral untreated defects (Table 6:III, p=0.028); although
aggrecan immunostaining for defects treated with KLD received a score of 2.7, it was not
different from the contralateral untreated control (Table 6:I, p=0.526). This is in contrast to
the difference observed in Safranin-O staining between defects treated with KLD and the
contralateral untreated defects. In group 2, KLD+CF treatment elicited a tissue with higher
aggrecan detected by immunostaining vs. the contralateral untreated control (Table 6:I,
p=0.041). In addition, although defects treated with KLD+CF received the highest collagen
II immunostaining score of all the groups, 3.4, this was not different from its contralateral
untreated control (Table 6:III, p=0.110). Comparing all defects, treated defects had more
collagen II (2.9 (2.2, 3.6) treated; 1.6 (0.9, 2.2) untreated; treatment p=0.001) and increased
aggrecan (2.9 (2.3, 3.4) treated; 2.1 (1.6, 2.7) untreated; treatment p=0.056) compared to
untreated defects; there were no differences among groups (group p=0.293). There were
similar levels of collagen I immunostaining found in all the defects (treatment p=0.471,
group p=0.919), consistent with the observation of mostly fibrocartilage seen in the gross
scoring (Table 6:II). Overall, within the repair tissues, collagen II immunostaining was
observed deeper in the sections and collagen I immunostaining was seen more in the
superficial. Aggrecan immunostaining was noted to have a more generalized distribution,
but more positive staining was seen deeper in the repair tissue.
DISCUSSION
Treatment of full-thickness articular cartilage defects with the self-assembling peptide KLD
(group 1) markedly improved cartilage regeneration, as seen by significant increases in
cumulative histology score, Safranin-O staining, and collagen II immunostaining, compared
to critically-sized contralateral untreated defects. KLD has several advantages as a material
due to its ability to be injected arthroscopically into a defect, assemble on contact with
tissue, and promote cartilage regeneration without inducing an immune response. Adding
TGF-β1, dexamethasone, and IGF-1 to KLD (group 2) resulted in increased aggrecan
immunostaining compared to its contralateral untreated defect, but in general did not result
in any additional beneficial or deleterious effects compared to KLD alone (group 1).
Motivated by in vitro results supporting BMSC chondrogenesis33,34,38, we delivered these
factors with allogeneic BMSCs in KLD in vivo (group 3). However, this treatment resulted
in a poorer repair than with KLD or KLD+CF. This is similar to other reports of fibrous
tissue formation after BMSC treatment23,24,26, interpreted as a negative result.
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In our rabbit model, the presence of a full-thickness defect allowed bone marrow to infiltrate
the defect46 and act as a cell source, similar to abrasion arthroplasty and subchondral bone
microfracture surgical techniques. The positive healing response seen with KLD treatment
(group 1) demonstrates that the scaffold supports cell migration and further chondrogenesis
of these cells in vivo. The high porosity of this scaffold (~99.6% water content31) is in
agreement with a recent in vivo study in rabbits by Ikeda et al.47 demonstrating that
scaffolds with >85% porosity promoted migration of bone marrow cells into polymer
scaffolds and with an in vitro study by Wang et al.48 demonstrating endothelial cell
migration into several types of self-assembling hydrogels.
Regarding group 2, KLD+CF treatment, our results raise the issues of whether the CF dose
was appropriate to improve endogenous cell response and whether cells migrating into the
scaffold in vivo respond differently to these CFs than in vitro and thereby require different
stimulation. The inclusion of CFs did not show increased chondrogenesis over KLD alone
(group 1) as determined by cumulative histology score, Safranin-O, aggrecan, and type II
collagen immunostaining. Similar to these results, Holland et al.13 reported that TGF-β1 and
IGF-1 delivered in gelatin microparticles within an acellular oligo(poly(ethylene glycol)
fumarate) (OPF) scaffold resulted in repair no different than in empty defects, despite
positive results in vitro. That study also delivered IGF-1 alone and found that this growth
factor alone resulted in a significantly improved repair. In addition, other studies have
looked at delivering IGF-1 alone in vivo and have reported similar positive results4,16. While
we did not test the effects of IGF-1 alone in this study, our results emphasize the need for
further understanding of the combination of IGF-1 with other CF in vivo in order to take
advantage of its characteristic anabolic properties.
The intra-articular use of TGF-β1 remains controversial due to the pro-inflammatory
response by the synovium seen at certain concentrations. Van der Kraan and van den Berg et
al. have studied the interaction of TGF-β1 with various joint tissues and have shown that
while TGF-β1 can stimulate proteoglycan production in cartilage, when it is exposed to
synovial tissue, synovial fibrosis can occur; TGF-β1-induced osteophyte formation is also
common18. Mi et al.17 showed that injection of recombinant adenoviral vector for hTGF-β1
into the knee joint space through the patellar tendon (resulting in ~8.75 ng TGF-β1)
dramatically increased joint inflammation, though this dose is more than 6-fold higher than
our total dose of 1.4 ng. Accordingly, we did not observe these effects when TGF-β1 was
added to the peptide alone (group 2). In contrast, when TGF-β1 was added in combination
with BMSCs (group 3), osteophyte formation increased, suggesting an interaction of TGF-
β1 with these cells was responsible for the increased osteogenesis rather than the presence of
TGF-β1 alone in the joint (group 2). This finding is similar to results recently published by
Guo et al.27, in which 600 ng of TGF-β1 per mL of hydrogel was used in combination with
BMSCs in an OPF scaffold. Furthermore, we observed a detrimental increase in osteophyte
formation and distortion of normal joint anatomy when, in the same rabbit, 1.4 ng TGF-
β1+BMSCs were placed in one joint and 0.7 ng TGF-β1+BMSCs in the contralateral joint49.
The authors were surprised at this result given the total body dose of TGF-β1 was only 1.5x
what was used in group 2 or group 3 and the cell numbers 2-fold greater. While the amount
of TGF-β1 delivered in group 3 of our study was lower than that in the Mi17 study, and we
attempted to deliver TGF-β1 in a controlled fashion, it is still possible that this TGF-β1 level
was too high to beneficially induce chondrogenesis when combined with BMSCs, despite
the inclusion of dexamethasone, which has been shown to enhance chondrogenesis
compared to TGF-β1 alone9,50. A study by Fan et al. using only 0.8 ng of TGF-β1 with
BMSCs in a gelatin-chondroitin-hyaluronate tri-copolymer scaffold reported improved
rabbit cartilage defect healing compared to treatment with BMSCs implanted in a scaffold
without TGF-β1. Taken together, these studies suggest that while the amount of TGF-β1 we
chose combined with BMSCs effectively induces chondrogenesis in vitro38, additional
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research is needed to determine a successful strategy for optimizing chondrogenesis of
BMSCs in vivo, and interactions with synovial tissues must be considered.
Due to the often noted ability of cartilage defects in young/skeletally immature rabbits to
heal well naturally46, we used skeletally mature rabbits with average age of 11 months and
critically-sized defects in order to test the ability of treatment to improve adult animal
healing. Although full-thickness defects were used, defects only entered the subchondral/
trabecular bone, resulting in contralateral untreated defects that do not heal spontaneously by
12 weeks. These results are similar to other studies using similar-aged rabbits and defect
sizes. A limitation of our model is the lack of enough tissue to perform direct biochemical
assessment in addition to histological and immunohistochemical measurements in this study.
However, the purpose of the present study was to perform an initial trial prior to a larger
animal study where such additional measures will be utilized, since ample tissue will be
available.
In summary, the self-assembling peptide hydrogel KLD offers a new material suitable for
further testing in a clinically relevant defect in a large animal. We demonstrated improved
filling of osteochondral defects and improved cartilage repair, as seen by cumulative
histology score, Safranin-O staining, and type II collagen immunostaining. In this small
animal model, the full-thickness defect provided access to the marrow, similar in concept to
abrasion arthroplasty or spongialization in large animal models (goat, sheep, horse, human),
and suggests that combining KLD with these techniques may offer an improvement over
current practice. Ongoing studies include the evaluation of KLD in a clinically relevant
sized equine defect co-treated with microfracture and subjected to strenuous exercise,
compared to defects treated with microfracture alone.
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Fig 1.
Gross necropsy photographs of treated and untreated joints in KLD, KLD+CF, and KLD
+CF+BMSCs.
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Fig 2.
Safranin-O staining. Images showing histological evaluation of representative treatment
groups and representative contralateral control knees. Treatment and contralateral pictures
were representative of the mean scores and were taken from different animals for KLD and
KLD+CF+BMSCs, and from the same animal for KLD+CF. Scale bar = 1 mm.
Miller et al. Page 14
Osteoarthritis Cartilage. Author manuscript; available in PMC 2012 January 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Miller et al. Page 15
Ta
bl
e 
1
Tr
ea
tm
en
t g
ro
up
s w
ith
 a
m
ou
nt
s d
el
iv
er
ed
 p
er
 a
ni
m
al
.
G
ro
up
n
K
L
D
 (μ
g)
bK
L
D
 (μ
g)
T
G
F-
β1
 (n
g)
bI
G
F 
(n
g)
St
re
pt
av
id
in
 (n
g)
D
ex
 (n
g)
B
M
SC
s (
×1
03
)
1 
(K
L
D
)
6
48
0.
48
0
0
0
0
0
2 
(K
L
D
+C
F)
6
48
0.
48
1.
4
4.
1
30
.7
0.
6
0
3 
(K
L
D
+C
F+
B
M
SC
s)
7
48
0.
48
1.
4
4.
1
30
.7
0.
6
15
0
Osteoarthritis Cartilage. Author manuscript; available in PMC 2012 January 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Miller et al. Page 16
Table 2
Gross Observations Scoring System.
Feature Score
I. Joint Observation
Normal appearance 0
Slight inflammation 1
Moderate inflammation 2
Severe inflammation 3
II. Incision Appearance
Normal appearance 0
Slight inflammation 1
Moderate inflammation 2
Severe inflammation 3
Slight dehiscence (incision basically intact) 4
Marked dehiscence (requires intervention) 5
Active infection 6
Healing infections 7
III. Muscle wastage at the time of necropsy in treated vs untreated limbs
Circumferential measurement at the proximal aspect of the patella (cm)
IV. Angle of Stifle: Change in normal angle (if any)
None, within normal limits 0
Abnormal 1
V. Inflammation/Swelling
None, within normal limits 0
Abnormal 1
VI. Trauma/Damage
None, within normal limits 0
Abnormal 1
VII. Infection/Discharge
None, within normal limits 0
Abnormal 1
VIII. Presence of Osteophytes and other Osteoarthritic Changes
None, within normal limits 0
Abnormal 1
IX. Articular Surface Integrity, Contour, and Congruity
Normal 0
Abnormal 1
X. Presence of Loose Bodies in Synovial Fluid
None, within normal limits 0
Abnormal 1
XI. Injury to Apposing Articular Surface
None, within normal limits 0
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Feature Score
Abnormal 1
XII. Synovial Membrane Appearance
Normal 0
Slight 1
Mild 2
Moderate 3
Severe 4
XIII. Cartilage Attachment
This category describes on average the defect repair tissue attachment with the surrounding normal cartilage. Possible responses were:
Normal Attachment 0
Moderate Attachment 1
Mild Attachment 2
Slight Attachment 3
No Attachment 4
XIV. Bone Attachment
This category describes the firmness of the repair tissue attachment to the bone at the base of the defect. Possible responses were:
Similar to Surrounding Cartilage 0
Slightly Soft-vs-Surrounding Cartilage 1
Mildly Soft-vs-Surrounding Cartilage 2
Moderately Soft-vs-Surrounding Cartilage 3
Marked Softening-vs-Surrounding Cartilage 4
XV. Firmness
This category describes on average the firmness of the repair tissue to normal surrounding articular cartilage. Possible responses were:
Similar Compared to Surrounding Cartilage 0
Slightly Soft Compared to Surrounding Cartilage 1
Mildly Soft Compared to Surrounding Cartilage 2
Moderately Soft Compared to Surrounding Cartilage 3
Marked Softening Compared to Surrounding Cartilage 4
XVI. Blood
This category describes the presence or absence of hemorrhage associated with the defect area or its periphery. Possible responses
were:
Fresh Blood, Active Hemorrhage at Time of Surgery 1
Old Blood, No Active Hemorrhage at Time of Surgery 2
No Blood Visualized at Time of Surgery 3
XVII. Shape
This category describes the margin of the defect as it relates to the original geometry at time 0 (creation). Possible responses were:
No Apparent in Damage Tissue Beyond Defect 0
Degeneration in Tissue Beyond Defect 1
XVIII. Grade (Overall quality of repair)
This category describes the overall subjective evaluation of the repair tissue by the evaluator.
Criteria used to determine the grade were:
(1) Attachment of repair tissue to the surrounding normal articular cartilage
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Feature Score
(2) Level (height) and undulation of the repair tissue surface as compared to the surrounding normal articular cartilage
(3) Color of the repair tissue, where white homogenous tissue without a fibrous like appearance is used as the “gold standard.”
Tissue Not Present to Grade 0
Poor 1
Fair 2
Good 3
Excellent 4
XIX. Level
This category describes the level of repair tissue filling in association with the surrounding normal articular cartilage.
Possible responses in relation to the surrounding normal articular cartilage were:
Mildly Recessed 1
Slightly Recessed 2
Leveled 3
Slightly Elevated 4
Mildly Elevated 5
Moderately Elevated 6
XX. Color
This category describes the color of the repair tissue. When repair tissue is characterized by two colors, the predominate color is
indicated first. Possible responses were:
Red 1
White/Red 2
Yellow 3
Yellow/White 4
White/Yellow 5
White 6
XXI. Surface
This category describes the relative undulation of the repair tissue surface. Possible responses were:
Non-Undulating 1
Slightly Undulating 2
Mildly Undulating 3
Moderatley Undulating 4
XXII. Area
Percent of Surface Area Filled in Defect (0–100%)
XXIII. Volume
Percent of Volume Filled in Defect (0–100%)
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Table 3
Modified O’Driscoll Histological Scoring System.
Feature Score
I. Nature of the Repair Tissue
Some Fibrocartilage, mostly nonchondrocytic cells 0
Mostly Fibrocartilage 1
Mixed Hyaline and Fibrocartilage 2
Mostly Hyaline Cartilage 3
Hyaline Cartilage 4
II. Surface Regularity
Severe Disruption, Including Fibrillation 0
Fissures 1
Superficial Horizontal Lamination 2
Smooth and Intact 3
III. Structural Integrity (morphologic zone reconstitution)
Severe Disintegration 0
Slight Disruption, Including Cysts 1
Normal 2
IV. Thickness
0% – 50% of Normal Cartilage 0
50% – 100% of Normal Cartilage 1
100% of Normal Adjacent Cartilage 2
V. Bonding to Adjacent Cartilage
Not Bonded 0
Bonded at One End or Partially at Both Ends 1
Bonded at Both Ends of Graft 2
VI. Hypocellularity
Moderate Hypocellularity 0
Slight Hypocellularity 1
Normal Cellularity 2
VII. Chondrocyte Clustering
25% – 100% of the Cells 0
< 25% of the Cells 1
No Clusters 2
VIII. Freedom from Degenerative Changes in Adjacent Cartilage
Severe Hypocellularity, Poor or No Staining 0
Mild or Moderate Hypocellularity, Slight Staining 1
Normal Cellularity, Mild Clusters, Moderate Staining 2
Normal Cellularity, No Clusters, Normal Staining 3
IX. Reconstitution of Subchondral Bone
No Subchondral Bone Reconstitution 0
Minimal Subchondral Bone Reconstitution 1
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Feature Score
Reduced Subchondral Bone Reconstitution 2
Normal 3
X. Inflammatory Response in Subchondral Bone Region
Severe 0
Moderate 1
None/Mild 2
XI. Safranin-O Staining
None 0
Slight 1
Moderate 2
Normal 3
XII. Cumulative Histology Score (sum of above scores) 0–28
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